AstraZeneca Results Presentation Deck
BioPharmaceuticals: New CVRM
16% growth driven by Farxiga and Renal
$m
1,500
1,250
1,000
750
500
250
Q1 2018
Q2 2018
Q3 2018
Q4 2018
New CVRM
16% growth
Q1 2019
Q2 2019
Q3 2019
Farxiga Brilinta Diabetes Renal
Total revenue at actual exchange rates; changes
at CER and for H1 2021, unless stated otherwise.
15
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
$m
750
500
250
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Farxiga
53% growth - the fastest-growing SGLT2i globally
Q2 2019
Q3 2019
Q4 2019
US Europe
EROW EM
Total revenue at actual exchange rates; changes
at CER and for H1 2021, unless stated otherwise.
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
US +27%
Strong market share growth boosted
by HFrEF¹ indication and CKD launch
Europe +51%
Strong volume growth boosted
by launch of HFrEF indication
EM +77%
Benefit from NRDL inclusion in China
and strong growth outside China
4
1. Heart failure with reduced ejection fraction.View entire presentation